Ok_老虎社区_美港股上老虎

JazzyTazzy
2021-02-14

Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO

PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi and U.S. group Transla

Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":386469204,"tweetId":"386469204","gmtCreate":1613258317708,"gmtModify":1634554099655,"author":{"id":3567658644109643,"idStr":"3567658644109643","authorId":3567658644109643,"authorIdStr":"3567658644109643","name":"JazzyTazzy","avatar":"https://static.tigerbbs.com/cd4a9dd018fb8d987d99b520851b607a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/386469204","repostId":2111807728,"repostType":2,"repost":{"id":"2111807728","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613256424,"share":"https://www.laohu8.com/m/news/2111807728?lang=&edition=full","pubTime":"2021-02-14 06:47","market":"us","language":"en","title":"Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2111807728","media":"Reuters","summary":"PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi    and U.S. group Transla","content":"<html><body><p>PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>    and U.S. group Translate Bio</p><p>  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.</p><p>   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.</p><p>   In December last year, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.  </p><p>   \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.</p><p>   The CEO gave no other details. Officials at Sanofi were not available for comment.</p><p>   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .</p><p>   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.  </p><p>   To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.  </p><p>   Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.</p><p>   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.</p><p> (Reporting by Matthias Blamont; Editing by Dominique Vidalon)</p><p>((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-14 06:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>    and U.S. group Translate Bio</p><p>  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.</p><p>   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.</p><p>   In December last year, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.  </p><p>   \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.</p><p>   The CEO gave no other details. Officials at Sanofi were not available for comment.</p><p>   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .</p><p>   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.  </p><p>   To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.  </p><p>   Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.</p><p>   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.</p><p> (Reporting by Matthias Blamont; Editing by Dominique Vidalon)</p><p>((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","TBIO":"TELESIS BIO","PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111807728","content_text":"PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi    and U.S. group Translate Bio  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.   In December last year, Sanofi had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.     \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.   The CEO gave no other details. Officials at Sanofi were not available for comment.   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.     To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.     Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly. (Reporting by Matthias Blamont; Editing by Dominique Vidalon)((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))","news_type":1},"isVote":1,"tweetType":1,"viewCount":344,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}